Research progress in the cardiovascular adverse reactions of sorafenib and its mechanisms
10.12092/j.issn.1009-2501.2021.11.012
- Author:
Jing LING
1
;
Qinghai ZHANG
1
;
Zhaofen ZHENG
1
;
Jing LING
2
;
Qinghai ZHANG
2
;
Zhaofen ZHENG
2
Author Information
1. Department of Cardiology, The First Affiliated Hospital of Hunan Normal University/Hunan Provincial People's Hospital
2. Clinical Medicine Research Center of Heart Failure of Hunan Province
- Publication Type:Journal Article
- Keywords:
Cardiovascular adverse reactions;
Sorafenib;
Tyrosine kinase inhibitors;
VEGFR
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(11):1300-1308
- CountryChina
- Language:Chinese
-
Abstract:
Sorafenib is a multi-tyrosine kinase inhibitor targeting a variety of tyrosine kinase receptors involved in angiogenesis, tumor growth and tumor metastasis. It is currently widely used in renal cell carcinoma and hepatocellular carcinoma's treatment. Sorafenib prolongs overall survival of many patients with malignant tumors. However, the adverse drug reactions, especially serious cardiovascular adverse reactions, still reduce its clinical benefits. Therefore, it is important to prevent or reduce adverse cardiovascular reactions caused by sorafenib. This article reviews the adverse cardiovascular reactions and its possible mechanisms caused by sorafenib.
